Verastem Inc

NASDAQ:VSTM   3:59:55 PM EDT
1.71
+0.12 (+7.91%)
5:25:14 PM EDT: $1.79 +0.09 (+4.99%)
Other Pre-Announcement

Verastem Oncology Reports Q3 2020 Financial Results

Published: 11/09/2020 22:26 GMT
Verastem Inc (VSTM) - Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress.
Q3 Adjusted Non-GAAP Earnings per Share $0.11.
Q3 Earnings per Share $0.08.
Q3 Revenue $78.6 Million Versus $9.0 Million.
Q3 Revenue Estimate $26.6 Million -- Refinitiv Ibes Data (analyst estimates).
Q3 Earnings per Share Estimate $0.04 -- Refinitiv Ibes Data (analyst estimates).
Expects Its 2020 Operating Expenses to Be Approximately 40% Lower Than Its 2019 Operating Expenses.
Expects Total Operating Expenses for Full Year 2020 to Be in Range of $80 Million to $90 Million.
Beginning in 2021 Verastem Expects Its Annual Operating Expenses to Be Approximately $50 Million.
Ended Q3 of 2020 With Cash, Cash Equivalents and Short-term Investments of $205.7 Million.